Moderna (MRNA) Down 92% from All-Time High – What's Next?
Overview:
Moderna (MRNA) has fallen sharply, trading 92% below its all-time high of $497.49 (reached in 2021). With this massive decline, investors might wonder: Is the stock poised for a recovery or headed lower?
Key Insights:
Support Levels:
Current price hovers near the 2020 pre-pandemic breakout zone (~$30-$40), a strong historical support area.
Catalysts to Watch:
Pipeline Updates: Moderna's future depends heavily on non-COVID vaccine developments. Any positive trial data could spark a rally. Broader Market Trends: If biotech stocks gain traction, MRNA could benefit as a high-beta play.
Moderna (MRNA) has fallen sharply, trading 92% below its all-time high of $497.49 (reached in 2021). With this massive decline, investors might wonder: Is the stock poised for a recovery or headed lower?
Key Insights:
Support Levels:
Current price hovers near the 2020 pre-pandemic breakout zone (~$30-$40), a strong historical support area.
Catalysts to Watch:
Pipeline Updates: Moderna's future depends heavily on non-COVID vaccine developments. Any positive trial data could spark a rally. Broader Market Trends: If biotech stocks gain traction, MRNA could benefit as a high-beta play.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.